MESOBLAST LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.11 AUD | -.--% |
|
-5.53% | +258.06% |
| May. 01 | Mesoblast Limited Announces Board and Committee Changes | CI |
| Apr. 01 | ADRs End Higher; Connect Biopharma Climbs 26% | DJ |
| Sales 2024 * | 11.52M 7.66M | Sales 2025 * | 24.85M 16.53M | Capitalization | 1.27B 843M |
|---|---|---|---|---|---|
| Net income 2024 * | -103M -68.52M | Net income 2025 * | -121M -80.49M | EV / Sales 2024 * | 115 x |
| Net Debt 2024 * | 55.05M 36.62M | Net Debt 2025 * | 93.28M 62.05M | EV / Sales 2025 * | 54.7 x |
| P/E ratio 2024 * |
-10.5
x | P/E ratio 2025 * |
-10.3
x | Employees | 83 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mesoblast Limited
More recommendations
More press releases
More news
| 1 week | -5.53% | ||
| 1 month | +12.12% | ||
| 3 months | +276.27% | ||
| 6 months | +174.07% | ||
| Current year | +258.06% |
1 week
1.06
1.30
1 month
1.021.30
Current year
0.261.30
1 year
0.261.43
3 years
0.262.34
5 years
0.265.70
10 years
0.265.88
| Managers | Title | Age | Since |
|---|---|---|---|
Silviu Itescu
FOU | Founder | 67 | 04-06-07 |
Andrew Chaponnel
DFI | Director of Finance/CFO | - | 12-05-31 |
| Chief Operating Officer | 60 | 20-07-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eric Rose
CTO | Chief Tech/Sci/R&D Officer | 73 | 13-04-14 |
Joseph Swedish
BRD | Director/Board Member | 72 | 18-06-17 |
William Burns
BRD | Director/Board Member | 76 | 14-03-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 746 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1.11 | -.--% | 11,223,950 |
| 24-05-30 | 1.11 | -9.76% | 12,254,200 |
| 24-05-29 | 1.23 | -2.38% | 8,142,886 |
| 24-05-28 | 1.26 | +9.09% | 17,829,870 |
| 24-05-27 | 1.155 | -1.70% | 8,412,678 |
Delayed Quote Australian S.E., May 31, 2024 at 02:10 am EDT
More quotes
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Companyâs Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Companyâs licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.11
AUD
Average target price
1.1
AUD
Spread / Average Target
-0.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +258.06% | 841M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- MSB Stock
